Cargando…

Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study

Detalles Bibliográficos
Autores principales:	Moreno, Carol, Delgado, Julio, Byrd, John C., Zvagelsky, William L., Suzuki, Samuel, Hsu, Emily, James, Danelle F., Montserrat, Emili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585694/ https://www.ncbi.nlm.nih.gov/pubmed/29855051 http://dx.doi.org/10.1111/bjh.15397

Ejemplares similares

慢性淋巴细胞白血病研究进展——第十六届国际慢性淋巴细胞白血病工作组(iwCLL)会议报道
Publicado: (2016)

CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report
por: Baumann, Tycho, et al.
Publicado: (2020)

When CLL meets COVID-19
por: Montserrat, Emili
Publicado: (2020)

Critical molecular pathways in CLL therapy
por: Ferrer, Gerardo, et al.
Publicado: (2018)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
por: Wang, Yucai, et al.
Publicado: (2021)

Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy: On behalf of CLL commission of Lombardy Hematology Network (REL)
por: Reda, Gianluigi, et al.
Publicado: (2020)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
por: Gentile, Massimo, et al.
Publicado: (2020)

Significance of t (8: 14) in CLL?
por: Lakshmaiah, K. C., et al.
Publicado: (2010)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Tumor suppressors revival in CLL
por: Carrà, Giovanna, et al.
Publicado: (2017)

CLL und Covid-19
por: Behrend, Christian
Publicado: (2022)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
por: Decker, William K., et al.
Publicado: (2012)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
por: Jin, Xin, et al.
Publicado: (2022)

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
por: Scarfò, Lydia, et al.
Publicado: (2020)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Reactivating nuclear PTEN to treat CLL
por: Bernardi, Rosa, et al.
Publicado: (2017)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

Schlechte Impfantwort bei CLL-Patienten
por: Behrend, Christian
Publicado: (2021)

Schlechte Impfantwort bei CLL-Patienten
por: Behrend, Christian
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Glabellar and auricular leukemia cutis in CLL
por: Steinman, Bradley, et al.
Publicado: (2022)

NF-kB and the CLL microenvironment
por: O’Donnell, Alice, et al.
Publicado: (2023)

Immediate COVID-19 treatment in CLL
por: Niemann, Carsten Utoft
Publicado: (2023)

Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells
por: Ghamlouch, Hussein, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_38n0neg7ens2lh4mfgm1mi25ov